Docetaxel clinical trials
Also written Taxotere, RP56976, HB1801 and Docefrez.
Includes 3 studies of Liposomal Docetaxel and 3 studies of Nanoparticle Albumin-Bound Docetaxel.
Related medicines add 8 studies
Counted the way a researcher would: Docetaxel with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Docetaxel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Docetaxel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 May 1996 · TAXOTERE · NDA 020449 (FDA, Drugs@FDA)
- European Union
- 27 Nov 1995 · Taxotere · EMEA/H/C/000073 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
1,159 studies that test it; most in 2004 (99)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1994 | 1 |
| 1995 | 3 |
| 1996 | 2 |
| 1997 | 11 |
| 1998 | 17 |
| 1999 | 35 |
| 2000 | 27 |
| 2001 | 40 |
| 2002 | 55 |
| 2003 | 76 |
| 2004 | 99 |
| 2005 | 88 |
| 2006 | 70 |
| 2007 | 83 |
| 2008 | 63 |
| 2009 | 44 |
| 2010 | 41 |
| 2011 | 35 |
| 2012 | 27 |
| 2013 | 31 |
| 2014 | 30 |
| 2015 | 29 |
| 2016 | 30 |
| 2017 | 19 |
| 2018 | 27 |
| 2019 | 16 |
| 2020 | 22 |
| 2021 | 23 |
| 2022 | 18 |
| 2023 | 29 |
| 2024 | 23 |
| 2025 | 25 |
| 2026 | 19 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 203 · Other 961
Sanofi (51) · National Cancer Institute (NCI) (31) · M.D. Anderson Cancer Center (29) · Alliance for Clinical Trials in Oncology (23) · Hoffmann-La Roche (20) · Dana-Farber Cancer Institute (19) · SWOG Cancer Research Network (19) · Memorial Sloan Kettering Cancer Center (18)
Often tested with
Tested in the same studies.
Cisplatin (189) · Gemcitabine (122) · Carboplatin (104) · Fluorouracil (95) · Capecitabine (90) · Oxaliplatin (74) · Cyclophosphamide (71) · Doxorubicin (64)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
- One of Taxoids source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 78 phase 3 studies under way
Docetaxel is the comparator. A study of two new drugs counts under both.
- 4Paclitaxel · Fudan University, Henan Cancer Hospital · next primary completion Jun 2028
- 3Sacituzumab tirumotecan · Merck Sharp & Dohme LLC · next primary completion May 2027
- 3Desoxyepothilone B · Beijing Biostar Pharmaceuticals Co., Ltd., Sun Yat-sen University
- 2Tambotatug pelitecan · MediLink Therapeutics (Suzhou) Co., Ltd. · next primary completion Dec 2027
- 2Datopotamab deruxtecan · Daiichi Sankyo, AstraZeneca · next primary completion Jan 2029
- 2Trastuzumab rezetecan · Jiangsu HengRui Medicine Co., Ltd. · next primary completion Jun 2027
- 2Sacituzumab govitecan · Gilead Sciences, National Cancer Institute (NCI) · next primary completion Dec 2030
- 2Pembrolizumab · Merck Sharp & Dohme LLC, National Cancer Institute (NCI) · next primary completion May 2027
Reaching primary completion within a year · 34, 8 in phase 3
Studies that test Docetaxel, phase 3 first.
- Nov 2026A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)Phase 3 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)Phase 3 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerPhase 3 · Karolinska Institutet
- Dec 2026A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerPhase 3 · Shanghai JMT-Bio Inc.
- Dec 2026Study of Comparing of With and Without Sequential Therapy of S-1Phase 3 · Zhejiang University
- Apr 2027A Study to Test Radium-223 With Docetaxel in Patients With Prostate CancerPhase 3 · Memorial Sloan Kettering Cancer Center
- Apr 2027Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction CancerPhase 2/3 · Ukrainian Society of Clinical Oncology
- May 2027Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerPhase 3 · Akeso
- Nov 2026Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaPhase 2 · Fudan University
- Dec 2026Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBCPhase 2 · University of Kansas Medical Center
Studies
Open first, then newest update. How each study uses Docetaxel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 1,164
- A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerRecruitingPhase 3Ferring PharmaceuticalsNCT06545955Written as Docetaxel
- Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure of First-Line ImmunotherapyRecruitingPhase 2Anhui Provincial HospitalNCT07925866Written as Docetaxel
- Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialRecruitingPhase 2City of Hope Medical CenterNCT06042569Written as Docetaxel
- Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT06931340Written as Docetaxel
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingPhase 2AstraZenecaNCT07069712Written as FLOT Chemotherapy
- Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate CancerNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07907653Written as Docetaxel
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT04633252Written as Docetaxel
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingPhase 2Jazz PharmaceuticalsNCT07102381Written as Docetaxel
- A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07900516Written as Docetaxel
- Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCRecruitingPhase 2CatalYm GmbHNCT07246863Written as Docetaxel
- PDT For Induction Therapy For Head And Neck CancerRecruitingPhase 2Massachusetts General HospitalNCT07214987Written as Docetaxel
- Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO TrialRecruitingPhase 2University of WashingtonNCT07698535Written as Docetaxel
- In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE TrialRecruitingPhase 1/2Mayo ClinicNCT06704191Written as Docetaxel
- NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT04615013Written as Docetaxel
- RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Not yet recruitingPhase 2Georgetown UniversityNCT07645326Written as Docetaxel
- De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNARecruitingPhase 2Mayo ClinicNCT05541016Written as Docetaxel
- Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2Mayo ClinicNCT06078709Written as Docetaxel
- Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived OrganoidsNot yet recruitingPhase 2Hospital Centre Biel/BienneNCT06227065Written as Docetaxel
- Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05027633Written as Docetaxel
- A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast CancerNot yet recruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07805135Written as HB1801
See all 1,164 studies that test Docetaxel →
Given beside what is tested · 673 — Docetaxel is usual care or a partner of the new treatment
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingPhase 1/2Boehringer IngelheimNCT06324357Written as Docetaxel
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06223568Written as Docetaxel
- Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response GenesRecruitingPhase 3Canadian Cancer Trials GroupNCT06439225Written as Docetaxel
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06952504Written as Docetaxel
- A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.RecruitingPhase 3AstraZenecaNCT07877818Written as FLOT Chemotherapy
- Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal AdenocarcinomaNot yet recruitingPhase 2Abramson Cancer Center at Penn MedicineNCT07059611Written as Docetaxel
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as Docetaxel
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 3Janssen Research & Development, LLCNCT07225946Written as Docetaxel
- Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor TherapyRecruitingPhase 3ImmunityBio, Inc.NCT06745908Written as Docetaxel
- An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2National Cancer Center Hospital EastNCT07018570Written as Docetaxel
- Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT05997615Written as Docetaxel
- A Study of ASP3082 in Adults With Advanced Solid TumorsRecruitingPhase 1Astellas Pharma IncNCT05382559Written as Docetaxel
- A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06123338Written as Docetaxel
- Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2/3SWOG Cancer Research NetworkNCT06616584Written as Docetaxel
- Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell TumorsNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07850973Written as Docetaxel
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsRecruitingPhase 1ExelixisNCT05176483Written as Docetaxel
- Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)Not yet recruitingPhase 3BeyondSpring Pharmaceuticals Inc.NCT07361484Written as Docetaxel
- TCb vs EC-T in High Risk ER+/HER2- Breast CancerRecruitingPhase 3Fudan UniversityNCT05901428Written as Docetaxel
- A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07828873Written as Docetaxel
- A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingPhase 2Shanghai Henlius BiotechNCT07824869Written as Docetaxel
Showing 20 of 673.
As the comparator · 256 — what is tested is compared with Docetaxel
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingPhase 3AstraZenecaNCT06989112Written as Docetaxel
- Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06780098Written as Docetaxel
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06524544Written as Docetaxel
- Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorRecruitingPhase 3OSE ImmunotherapeuticsNCT06472245Written as Docetaxel
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerRecruitingPhase 3BioNTech SENCT06340568Written as Docetaxel
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsRecruitingPhase 3AstraZenecaNCT07291037Written as Docetaxel
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07419295Written as Docetaxel
- A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07566052Written as Docetaxel
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)RecruitingPhase 3Revolution Medicines, Inc.NCT06881784Written as docetaxel
- A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Hoffmann-La RocheNCT07287150Written as Docetaxel
- A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)RecruitingPhase 3ORIC PharmaceuticalsNCT07723248Written as Docetaxel
- MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Not yet recruitingPhase 1/2Merck Sharp & Dohme LLCNCT07908524Written as Docetaxel
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07043725Written as Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection
- A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line TreatmentRecruitingPhase 3Biokin (Shanghai) Biopharmaceutical Co., Ltd.NCT07518147Written as Docetaxel
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06925737Written as Docetaxel
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 3AbbVieNCT04928846Written as Docetaxel
- A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT06891833Written as docetaxel
- FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.RecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07790380Written as Paclitaxel, Docetaxel, Irinotecan
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingPhase 3Daiichi SankyoNCT06644781Written as Docetaxel
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingPhase 2NRG OncologyNCT05408845Written as Docetaxel
Showing 20 of 256.
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Newly registered3
- Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure of First-Line ImmunotherapyNov 9, 2026NCT07925866
- Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate CancerOct 30, 2026NCT07907653
- A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.Oct 28, 2026NCT07900516
Codes
What other systems call Docetaxel · ClinicalTrials.gg INT006647
- MeSH (NLM) D000077143DocetaxelConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 15H5577CQDDOCETAXELConfirmed FDA, NLM, Wikidata
- RxNorm 72962Confirmed FDA, Wikidata
- Wikidata Q27126905docetaxel trihydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1526DocetaxelConfirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077143 | Docetaxel | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 15H5577CQD | DOCETAXEL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 72962 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27126905 | docetaxel trihydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1526 | Docetaxel | Confirmed FDA, Wikidata |
Also registered as docetaxel anhydrous (UNII 699121PHCA · RxNorm 1299922).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.